Note 8 - Share-based Compensation (Details Textual) - USD ($)			3 Months Ended		9 Months Ended
		Feb. 03, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			$ 3,896,000		$ 3,896,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					2 years 9 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed in Period, Gross (in shares)	[1]				24,263,424
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			725,000	4,235,000	13,830,000	4,440,000
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value			$ 265,000	$ 1,092,000	$ 5,611,000	$ 1,139,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)			389,599	170,325	1,197,899	396,885
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)			431,250	100,000	1,105,138	432,450
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)			91,605	72,500	1,913,185	72,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 37,000	$ 1,000	$ 607,000	$ 1,000
Viewpoint Molecular Targeting, Inc. [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed in Period, Gross (in shares)		24,263,424			24,263,424
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Per Share (in shares)					3.1642

[1] As a result of the Merger with Viewpoint, the Company assumed 24,263,424 option awards originally issued by Viewpoint into Perspective Therapeutic options with their original terms, effective upon the closing of the Merger on February 3, 2023. The share exchange ratio of 3.1642 was applied to convert Viewpoint's outstanding option awards for Viewpoint's common stock into option awards of Perspective Therapeutics common stock. The assumed options were fully vested upon closing of the Merger.